Oxford Cannabinoid Technologies Holdings Plc (OCTHF) Research

Oxford Cannabinoid Technologies Holdings Plc operates as a biopharmaceutical company, specializing in the discovery, development, and eventual market launch of cannabinoid-derived prescription medications. Its leading experimental drug, OCT461201, is a selective CB2 receptor agonist formulated as a solid oral dose. This compound is currently in the early, pre-clinical phase of development, being explored for its potential to alleviate visceral pain linked to Irritable Bowel Syndrome (IBS), alongside various neuropathic pain disorders like post-herpetic neuralgia. The company is also advancing another pipeline candidate, OCT130401, which is likewise in pre-clinical development, specifically aimed at treating trigeminal neuralgia. Established in 2017, Oxford Cannabinoid Technologies Holdings Plc maintains its corporate headquarters in London, United Kingdom.

Open Oxford Cannabinoid Technologies Holdings Plc (OCTHF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.